Pipeline of Novel Drugs

We have developed a rich pipeline of 21+ novel drugs which are next generation, substrate-specific p38α kinase immunomodulators, and 5 novel, next generation, substrate-specific ERK 1/2 immunomodulators to provide safe, selective, and effective therapies for rare and inflammatory diseases.

Our NextGen drugs are immunomodulatory and target specific inflammatory substrates while avoiding anti-inflammatory substrates in contrast to the first generation compounds, which were immunosuppressive, non-specific, and failed for safety or efficacy reasons.

While we are elevating our Lead Compound (Gen-1124) to the next level, we are simultaneously making progress on Indications 2 and 3. 

If rare and inflammatory diseases are your areas of interest, do reach out to us to explore synergies via partnership.

Get in touch with us!

We are based in Palo Alto, CA, and have a laboratory in Mountain View, CA.

We look forward to joining forces with you to cure rare and inflammatory diseases, fast!

Contact Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.